KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Financing Activities: 2009-2025

Historic Cash from Financing Activities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to -$1.2 billion.

  • Vertex Pharmaceuticals' Cash from Financing Activities fell 197.94% to -$1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 billion, marking a year-over-year decrease of 110.51%. This contributed to the annual value of -$1.5 billion for FY2024, which is 165.90% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Cash from Financing Activities stood at -$1.2 billion for Q3 2025, which was down 230.61% from -$349.2 million recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Cash from Financing Activities high stood at $47.7 million for Q2 2022, and its period low was -$1.2 billion during Q3 2025.
  • For the 3-year period, Vertex Pharmaceuticals' Cash from Financing Activities averaged around -$385.6 million, with its median value being -$357.5 million (2024).
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Cash from Financing Activities skyrocketed by 111.96% in 2022, and later tumbled by 2,172.83% in 2024.
  • Quarterly analysis of 5 years shows Vertex Pharmaceuticals' Cash from Financing Activities stood at -$336.2 million in 2021, then soared by 111.96% to $40.2 million in 2022, then slumped by 398.01% to -$119.8 million in 2023, then tumbled by 226.63% to -$391.3 million in 2024, then plummeted by 197.94% to -$1.2 billion in 2025.
  • Its Cash from Financing Activities was -$1.2 billion in Q3 2025, compared to -$349.2 million in Q2 2025 and -$680.4 million in Q1 2025.